Ultragenyx Pharmaceutical Inc.

RARE Healthcare Biotechnology

Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

14.54 0.63 −4.15%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
5/9
Altman Z
−3.57
Beneish M
−2.68
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Net Income
(245.87) (302.14) (197.61) (402.73) (186.57) (454.02) (707.42) (607.00) (569.00) (575.00)
Depreciation & Amortization
8.27 7.53 16.90 2.33 13.11 19.85 20.92 13.00 23.00 31.00
Non Cash Items (Other)
50.33 44.75 (85.06) 74.48 (63.43) 158.72 244.16 135.00 118.00 101.00
Accounts Receivable Change
— (5.17) (7.58) (20.10) 9.84 (5.43) (12.07) (23.00) (34.00) (31.00)
Change in inventories
— (0.76) (5.28) (4.45) (1.35) (3.12) (9.70) (7.00) (11.00) (6.00)
Accounts Payable Change
2.50 3.46 3.37 13.31 26.85 32.31 87.44 2.38 — —
Change in payables and accrued liability
32.19 (1.17) 2.36 13.31 26.85 32.31 79.85 (1.00) 47.00 24.00
Change in other assets and liabilities
(8.39) 3.11 (14.28) (8.22) 69.32 (87.00) 3.80 15.00 12.00 (10.00)
Operating Cash Flow
(160.97) (253.84) (290.57) (345.38) (132.22) (338.69) (380.46) (475.00) (414.00) (466.00)
Capital expenditures
(10.19) (2.79) (4.08) (24.83) (43.90) (73.09) (116.12) (44.00) (7.00) (6.00)
Change in intangibles (net)
— — — — — — (30.00) (3.00) (13.00) (15.00)
Net Aquisitions
— (142.80) — — — — (75.02) — — —
Short Term Investments Change (Net)
101.31 201.08 (199.58) 26.13 (172.44) (201.18) (79.75) 221.00 4.00 258.00
Long-Term Investments Change (Net)
— — — (14.34) 42.78 79.84 10.09 — — —
Other investing activities
— — 170.32 — (5.55) (0.94) (0.84) (6.00) (2.00) (1.00)
Investing cash flow
91.12 55.48 (33.33) (13.04) (179.12) (195.37) (291.65) 168.00 (18.00) 236.00
Repayment/Issuance of Debt (Net)
— (4.94) — — — — — — — —
Equity Repurchase (Common, Net)
138.68 141.21 336.85 365.07 600.51 119.04 10.81 387.00 399.00 86.00
Other financial activities
55.17 62.70 (87.70) 314.23 (0.24) (0.49) 490.40 1.00 — 392.00
Financing cash flow
138.68 136.27 336.85 679.31 600.27 118.55 501.21 388.00 399.00 478.00
Exchange Rate Adjustment
(0.06) 0.53 (0.47) (0.16) 1.12 (1.19) (1.07) 0.46 (2.00) 4.00
Change in Cash
68.75 (61.57) 12.48 320.72 290.05 (416.71) (171.98) 81.00 (35.00) 252.00
Beginning Cash
95.85 164.61 103.04 115.53 436.24 726.29 309.59 138.00 219.00 184.00
Ending Cash
164.61 103.04 115.53 436.24 726.29 309.59 137.60 219.00 184.00 436.00
Stock Based Compensation
48.31 68.01 80.11 82.00 85.74 104.95 130.38 135.00 158.00 153.00
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
26.30 (3.98) (24.79) (19.46) 104.66 (63.24) 61.87 (16.00) 14.00 (23.00)
Investments Change (Net)
101.31 201.08 (199.58) 11.79 (129.66) (121.34) (69.66) 221.00 4.00 258.00
Issuance/Purchase of Shares
138.68 141.21 336.85 365.07 600.51 119.04 10.81 387.00 399.00 86.00
Other line items
Revenue per Employee
0.00 0.01 0.08 0.14 0.30 0.31 0.28 0.34 0.43 0.49

Fold the line items

In millions of $ except per-share values · columns are period end dates